AU2003230836A1

AU2003230836A1 - Compounds and methods for inducing apoptosis in proliferating cells

Compounds and methods for inducing apoptosis in proliferating cells Download PDF

Info

Publication number: AU2003230836A1
Authority: AU; Australia
Prior art keywords: phenyl; pyrazol; trifluoromethyl; cancer; benzenecarboxyamide
Prior art date: 2002-04-08
Legal status : Abandoned

Application number

AU2003230836A

Other languages

English (en)

Inventor

Ching-Shin Chen

Ho-Pi Lin

Xueqin Song

Current Assignee

Ohio State University Research Foundation

Original Assignee

Ohio State University Research Foundation

Priority date

2002-04-08

Filing date

2003-04-08

Publication date

2003-10-27

2003-04-08 Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation

2003-10-27 Publication of AU2003230836A1 publication Critical patent/AU2003230836A1/en

Status Abandoned legal-status Critical Current

Links

230000006907 apoptotic process Effects 0.000 title claims description 164
150000001875 compounds Chemical class 0.000 title claims description 160
238000000034 method Methods 0.000 title claims description 77
230000001939 inductive effect Effects 0.000 title claims description 47
230000002062 proliferating effect Effects 0.000 title claims description 29
-1 2-fluorenyl Chemical group 0.000 claims description 291
206010028980 Neoplasm Diseases 0.000 claims description 56
206010060862 Prostate cancer Diseases 0.000 claims description 50
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 50
201000011510 cancer Diseases 0.000 claims description 42
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 40
238000011282 treatment Methods 0.000 claims description 40
229940111134 coxibs Drugs 0.000 claims description 39
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 34
239000003098 androgen Substances 0.000 claims description 29
230000002401 inhibitory effect Effects 0.000 claims description 26
150000003839 salts Chemical class 0.000 claims description 26
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 18
SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 18
125000003118 aryl group Chemical group 0.000 claims description 17
229940124530 sulfonamide Drugs 0.000 claims description 16
125000001188 haloalkyl group Chemical group 0.000 claims description 15
150000003456 sulfonamides Chemical class 0.000 claims description 15
125000000217 alkyl group Chemical group 0.000 claims description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
206010009944 Colon cancer Diseases 0.000 claims description 12
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 12
208000029742 colonic neoplasm Diseases 0.000 claims description 11
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
206010006187 Breast cancer Diseases 0.000 claims description 9
208000026310 Breast neoplasm Diseases 0.000 claims description 9
208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
206010033128 Ovarian cancer Diseases 0.000 claims description 9
206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
206010038389 Renal cancer Diseases 0.000 claims description 9
201000007455 central nervous system cancer Diseases 0.000 claims description 9
201000010982 kidney cancer Diseases 0.000 claims description 9
208000032839 leukemia Diseases 0.000 claims description 9
201000001441 melanoma Diseases 0.000 claims description 9
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 claims description 8
206010005003 Bladder cancer Diseases 0.000 claims description 8
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
125000002877 alkyl aryl group Chemical group 0.000 claims description 8
201000011199 bladder lymphoma Diseases 0.000 claims description 8
125000006492 halo alkyl aryl group Chemical group 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
201000005112 urinary bladder cancer Diseases 0.000 claims description 8
150000005840 aryl radicals Chemical group 0.000 claims description 7
125000003106 haloaryl group Chemical group 0.000 claims description 7
150000003254 radicals Chemical group 0.000 claims description 7
HNXYHZZMVJBSRC-UHFFFAOYSA-N 4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=C3C(C4=CC=CC=C4C=C3)=CC=2)=CC(C(F)(F)F)=N1 HNXYHZZMVJBSRC-UHFFFAOYSA-N 0.000 claims description 6
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 6
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
235000010290 biphenyl Nutrition 0.000 claims description 6
239000004305 biphenyl Substances 0.000 claims description 6
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 6
125000001475 halogen functional group Chemical group 0.000 claims description 6
125000001624 naphthyl group Chemical group 0.000 claims description 6
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 5
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 5
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
UDCKMNKMCPFWFT-UHFFFAOYSA-N 2-[4-[5-(4-benzylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F UDCKMNKMCPFWFT-UHFFFAOYSA-N 0.000 claims description 4
BPLQMOHKJAQQAM-UHFFFAOYSA-N 2-[4-[5-(4-propylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C(CC)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F BPLQMOHKJAQQAM-UHFFFAOYSA-N 0.000 claims description 4
PCEOVUCAASTBSM-UHFFFAOYSA-N 2-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C1=C(C=CC=2C3=CC=CC=C3C=CC1=2)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F PCEOVUCAASTBSM-UHFFFAOYSA-N 0.000 claims description 4
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims description 4
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
MQHBZJVDXQMNDJ-UHFFFAOYSA-N 2-[4-[5-(1H-indol-3-yl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N1C=C(C2=CC=CC=C12)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F MQHBZJVDXQMNDJ-UHFFFAOYSA-N 0.000 claims description 3
LMRYBTZLTFROTK-UHFFFAOYSA-N 2-[4-[5-(1H-pyrrol-2-yl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N1C(=CC=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F LMRYBTZLTFROTK-UHFFFAOYSA-N 0.000 claims description 3
UEPSNNRZXYJOBO-UHFFFAOYSA-N 2-[4-[5-(9H-fluoren-2-yl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C1=C(C=CC=2C3=CC=CC=C3CC1=2)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F UEPSNNRZXYJOBO-UHFFFAOYSA-N 0.000 claims description 3
NTFOSUUWGCDXEF-UHFFFAOYSA-N 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound CC1=CC=C(C)C(C=2N(N=C(C=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 NTFOSUUWGCDXEF-UHFFFAOYSA-N 0.000 claims description 3
DZZQBBYGNCJQAK-UHFFFAOYSA-N 4-[5-[4-(2-azidoethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(CCN=[N+]=[N-])=CC=2)=CC(C(F)(F)F)=N1 DZZQBBYGNCJQAK-UHFFFAOYSA-N 0.000 claims description 3
PHQSHZKOEWESCM-UHFFFAOYSA-N 4-[5-[4-(3-azidopropyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(CCCN=[N+]=[N-])=CC=2)=CC(C(F)(F)F)=N1 PHQSHZKOEWESCM-UHFFFAOYSA-N 0.000 claims description 3
WIKYBDNGZQKPBB-UHFFFAOYSA-N 4-[5-[4-(4-azidobutyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(CCCCN=[N+]=[N-])=CC=2)=CC(C(F)(F)F)=N1 WIKYBDNGZQKPBB-UHFFFAOYSA-N 0.000 claims description 3
FXCUTLXHVIAXCZ-UHFFFAOYSA-N 2-[4-[5-(2,4-dimethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound CC1=C(C=CC(=C1)C)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F FXCUTLXHVIAXCZ-UHFFFAOYSA-N 0.000 claims description 2
WAWVHPBQZPCSTH-UHFFFAOYSA-N 2-[4-[5-(2,5-dichlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F WAWVHPBQZPCSTH-UHFFFAOYSA-N 0.000 claims description 2
PSYCSFAQGQDVTO-UHFFFAOYSA-N 2-[4-[5-(3,4-dichlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC=1C=C(C=CC=1Cl)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F PSYCSFAQGQDVTO-UHFFFAOYSA-N 0.000 claims description 2
NKNWKBFLMWCUMR-UHFFFAOYSA-N 2-[4-[5-(4-azidophenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N(=[N+]=[N-])C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F NKNWKBFLMWCUMR-UHFFFAOYSA-N 0.000 claims description 2
NCOBIBSTMVBGLQ-UHFFFAOYSA-N 4-[5-[4-(4-butylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(CCCC)=CC=C1C1=CC=C(C=2N(N=C(C=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)C=C1 NCOBIBSTMVBGLQ-UHFFFAOYSA-N 0.000 claims description 2
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
HZXCJPDBOLVSEU-UHFFFAOYSA-N 4-[5-(4-butylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(CCCC)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 HZXCJPDBOLVSEU-UHFFFAOYSA-N 0.000 claims 1
210000004027 cell Anatomy 0.000 description 200
108010037462 Cyclooxygenase 2 Proteins 0.000 description 112
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 108
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 65
229960000590 celecoxib Drugs 0.000 description 58
230000000694 effects Effects 0.000 description 49
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 37
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
229910052739 hydrogen Inorganic materials 0.000 description 30
230000036515 potency Effects 0.000 description 30
239000000203 mixture Substances 0.000 description 29
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 26
229910052799 carbon Inorganic materials 0.000 description 25
239000003795 chemical substances by application Substances 0.000 description 25
230000007246 mechanism Effects 0.000 description 25
229960000371 rofecoxib Drugs 0.000 description 25
229910052757 nitrogen Inorganic materials 0.000 description 24
230000000692 anti-sense effect Effects 0.000 description 23
230000014509 gene expression Effects 0.000 description 23
230000005764 inhibitory process Effects 0.000 description 23
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 18
238000005481 NMR spectroscopy Methods 0.000 description 18
230000003833 cell viability Effects 0.000 description 18
229960003722 doxycycline Drugs 0.000 description 18
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 17
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 16
230000006698 induction Effects 0.000 description 16
239000000243 solution Substances 0.000 description 16
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 15
101710165576 Extracellular signal-regulated kinase 2 Proteins 0.000 description 15
238000004458 analytical method Methods 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 15
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 14
230000030833 cell death Effects 0.000 description 14
239000003814 drug Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
239000012980 RPMI-1640 medium Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 12
238000005421 electrostatic potential Methods 0.000 description 12
230000006882 induction of apoptosis Effects 0.000 description 12
239000012528 membrane Substances 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 11
230000004663 cell proliferation Effects 0.000 description 11
238000007667 floating Methods 0.000 description 11
238000001262 western blot Methods 0.000 description 11
AJFTZWGGHJXZOB-UHFFFAOYSA-N DuP 697 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(Br)=C1 AJFTZWGGHJXZOB-UHFFFAOYSA-N 0.000 description 10
KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 10
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 10
208000035475 disorder Diseases 0.000 description 10
239000007787 solid Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
230000001464 adherent effect Effects 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
238000009472 formulation Methods 0.000 description 9
125000000623 heterocyclic group Chemical group 0.000 description 9
239000002609 medium Substances 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
125000001424 substituent group Chemical group 0.000 description 9
238000005160 1H NMR spectroscopy Methods 0.000 description 8
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
230000002265 prevention Effects 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000012091 fetal bovine serum Substances 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
238000006366 phosphorylation reaction Methods 0.000 description 7
230000035945 sensitivity Effects 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 6
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 6
206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000001640 apoptogenic effect Effects 0.000 description 6
239000002585 base Substances 0.000 description 6
239000012267 brine Substances 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
230000030609 dephosphorylation Effects 0.000 description 6
238000006209 dephosphorylation reaction Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
238000001953 recrystallisation Methods 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 6
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000013592 cell lysate Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
238000005094 computer simulation Methods 0.000 description 5
238000001514 detection method Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
238000003119 immunoblot Methods 0.000 description 5
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000010992 reflux Methods 0.000 description 5
230000011664 signaling Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
239000003656 tris buffered saline Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 4
IKEURONJLPUALY-UHFFFAOYSA-N 4-hydrazinylbenzenesulfonamide;hydron;chloride Chemical compound [Cl-].NS(=O)(=O)C1=CC=C(N[NH3+])C=C1 IKEURONJLPUALY-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
238000002679 ablation Methods 0.000 description 4
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
QHIBGMPAPSVCSX-UHFFFAOYSA-N benzene;carbamic acid Chemical compound NC(O)=O.C1=CC=CC=C1 QHIBGMPAPSVCSX-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
150000003180 prostaglandins Chemical class 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
238000010186 staining Methods 0.000 description 4
230000005919 time-dependent effect Effects 0.000 description 4
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 4
ONVURFJRZJXWDD-UHFFFAOYSA-N 2-(4-sulfamoylphenyl)acetic acid Chemical compound NS(=O)(=O)C1=CC=C(CC(O)=O)C=C1 ONVURFJRZJXWDD-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010033040 Histones Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
235000013861 fat-free Nutrition 0.000 description 3
238000000799 fluorescence microscopy Methods 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
238000000302 molecular modelling Methods 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229940083575 sodium dodecyl sulfate Drugs 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical class CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
XMCRWEBERCXJCH-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1Cl XMCRWEBERCXJCH-UHFFFAOYSA-N 0.000 description 2
CYNFEPKQDJHIMV-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)ethanone Chemical compound CC(=O)C1=CC(Cl)=CC=C1Cl CYNFEPKQDJHIMV-UHFFFAOYSA-N 0.000 description 2
WBPAOUHWPONFEQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C(Cl)=C1 WBPAOUHWPONFEQ-UHFFFAOYSA-N 0.000 description 2
BKIHFZLJJUNKMZ-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC(C)=CC(C)=C1 BKIHFZLJJUNKMZ-UHFFFAOYSA-N 0.000 description 2
BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 2
HHAISVSEJFEWBZ-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(C(F)(F)F)C=C1 HHAISVSEJFEWBZ-UHFFFAOYSA-N 0.000 description 2
HGGWOSYNRVOQJH-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)acetic acid Chemical compound CS(=O)(=O)C1=CC=C(CC(O)=O)C=C1 HGGWOSYNRVOQJH-UHFFFAOYSA-N 0.000 description 2
LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 description 2
NYDILMNLVQIGDQ-UHFFFAOYSA-N 2-[4-[5-(4-chlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F NYDILMNLVQIGDQ-UHFFFAOYSA-N 0.000 description 2
GZBZHQIDNYNCKS-UHFFFAOYSA-N 2-[4-[5-[4-(2-bromoethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound BrCCC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F GZBZHQIDNYNCKS-UHFFFAOYSA-N 0.000 description 2
MJBOBMWXVDMJCB-UHFFFAOYSA-N 2-[4-[5-[4-(4-azidophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N(=[N+]=[N-])C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F MJBOBMWXVDMJCB-UHFFFAOYSA-N 0.000 description 2
CHGVLKBYTTYQNN-UHFFFAOYSA-N 2-[4-[5-[4-(4-bromobutyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound BrCCCCC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F CHGVLKBYTTYQNN-UHFFFAOYSA-N 0.000 description 2
CZZKVFZJGURGHZ-UHFFFAOYSA-N 2-[4-[5-[4-(4-tert-butylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F CZZKVFZJGURGHZ-UHFFFAOYSA-N 0.000 description 2
FWRDASJXTDIWMQ-UHFFFAOYSA-N 2-[4-[5-anthracen-9-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C1=CC=CC2=CC3=CC=CC=C3C(=C12)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F FWRDASJXTDIWMQ-UHFFFAOYSA-N 0.000 description 2
FSBKBFIGWCHKLN-UHFFFAOYSA-N 4-hydrazinylbenzamide;hydrochloride Chemical compound Cl.NNC1=CC=C(C(N)=O)C=C1 FSBKBFIGWCHKLN-UHFFFAOYSA-N 0.000 description 2
108090000672 Annexin A5 Proteins 0.000 description 2
102000004121 Annexin A5 Human genes 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
101150071146 COX2 gene Proteins 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
238000003775 Density Functional Theory Methods 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
239000012124 Opti-MEM Substances 0.000 description 2
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
108091006629 SLC13A2 Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 2
150000003857 carboxamides Chemical group 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000002113 chemopreventative effect Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 2
229940009976 deoxycholate Drugs 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
229950000484 exisulind Drugs 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
229960003552 other antineoplastic agent in atc Drugs 0.000 description 2
NODGRWCMFMEGJH-UHFFFAOYSA-N p-ethylacetophenone Chemical compound CCC1=CC=C(C(C)=O)C=C1 NODGRWCMFMEGJH-UHFFFAOYSA-N 0.000 description 2
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
238000002135 phase contrast microscopy Methods 0.000 description 2
LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000004088 simulation Methods 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000003335 steric effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000000565 sulfonamide group Chemical group 0.000 description 2
MVGSNCBCUWPVDA-MFOYZWKCSA-N sulindac sulfone Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000009424 underpinning Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 1
YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
HSDSKVWQTONQBJ-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C=C1C HSDSKVWQTONQBJ-UHFFFAOYSA-N 0.000 description 1
AWKBVLVKQQRRFQ-UHFFFAOYSA-N 1-(2,5-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC(C)=CC=C1C AWKBVLVKQQRRFQ-UHFFFAOYSA-N 0.000 description 1
CWILMKDSVMROHT-UHFFFAOYSA-N 1-(2-phenanthrenyl)ethanone Chemical compound C1=CC=C2C3=CC=C(C(=O)C)C=C3C=CC2=C1 CWILMKDSVMROHT-UHFFFAOYSA-N 0.000 description 1
VZYACYWXASWUFR-UHFFFAOYSA-N 1-(4-butylphenyl)-4,4,4-trifluorobutane-1,3-dione Chemical compound CCCCC1=CC=C(C(=O)CC(=O)C(F)(F)F)C=C1 VZYACYWXASWUFR-UHFFFAOYSA-N 0.000 description 1
MQESVSITPLILCO-UHFFFAOYSA-N 1-(4-butylphenyl)ethanone Chemical compound CCCCC1=CC=C(C(C)=O)C=C1 MQESVSITPLILCO-UHFFFAOYSA-N 0.000 description 1
LJHFYVKVIIMXQM-UHFFFAOYSA-N 1-(4-chlorophenyl)-4,4,4-trifluorobutane-1,3-dione Chemical compound FC(F)(F)C(=O)CC(=O)C1=CC=C(Cl)C=C1 LJHFYVKVIIMXQM-UHFFFAOYSA-N 0.000 description 1
KAVZYDHKJNABPC-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(S(C)(=O)=O)C=C1 KAVZYDHKJNABPC-UHFFFAOYSA-N 0.000 description 1
XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
SDNHLYIUINDGHM-UHFFFAOYSA-N 2-[4-[3-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]phenyl]acetamide Chemical compound FC(C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F)(F)F SDNHLYIUINDGHM-UHFFFAOYSA-N 0.000 description 1
KCJFXNDPLARTCD-UHFFFAOYSA-N 2-[4-[5-(2,4-dichlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F KCJFXNDPLARTCD-UHFFFAOYSA-N 0.000 description 1
RPYJZZBNYNYGCS-UHFFFAOYSA-N 2-[4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound CC1=C(C=C(C=C1)C)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F RPYJZZBNYNYGCS-UHFFFAOYSA-N 0.000 description 1
CISKYYWTRCOBQG-UHFFFAOYSA-N 2-[4-[5-(2-chlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC1=C(C=CC=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F CISKYYWTRCOBQG-UHFFFAOYSA-N 0.000 description 1
VKNYFJPEYKBCEH-UHFFFAOYSA-N 2-[4-[5-(3,5-dimethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound CC=1C=C(C=C(C=1)C)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F VKNYFJPEYKBCEH-UHFFFAOYSA-N 0.000 description 1
UHHMMRPYYYNRNG-UHFFFAOYSA-N 2-[4-[5-(4-butylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C(CCC)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F UHHMMRPYYYNRNG-UHFFFAOYSA-N 0.000 description 1
WHPGADHVYBAFAU-UHFFFAOYSA-N 2-[4-[5-(4-ethylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C(C)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F WHPGADHVYBAFAU-UHFFFAOYSA-N 0.000 description 1
CTJIOCWPZUIVHP-UHFFFAOYSA-N 2-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F CTJIOCWPZUIVHP-UHFFFAOYSA-N 0.000 description 1
QMIHSJBHVDDLTB-UHFFFAOYSA-N 2-[4-[5-[4-(2,3-dichlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC1=C(C=CC=C1Cl)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F QMIHSJBHVDDLTB-UHFFFAOYSA-N 0.000 description 1
KCJLNXKAOMYASO-UHFFFAOYSA-N 2-[4-[5-[4-(2-azidoethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N(=[N+]=[N-])CCC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F KCJLNXKAOMYASO-UHFFFAOYSA-N 0.000 description 1
IINIMOCHYWKTOU-UHFFFAOYSA-N 2-[4-[5-[4-(3,5-dichlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC=1C=C(C=C(C=1)Cl)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F IINIMOCHYWKTOU-UHFFFAOYSA-N 0.000 description 1
LICKQITYSIPAEC-UHFFFAOYSA-N 2-[4-[5-[4-(3-azidopropyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N(=[N+]=[N-])CCCC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F LICKQITYSIPAEC-UHFFFAOYSA-N 0.000 description 1
VFZKUGADLZGHFQ-UHFFFAOYSA-N 2-[4-[5-[4-(3-bromopropyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound BrCCCC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F VFZKUGADLZGHFQ-UHFFFAOYSA-N 0.000 description 1
ZJRHOWYRZCJNGN-UHFFFAOYSA-N 2-[4-[5-[4-(4-azidobutyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N(=[N+]=[N-])CCCCC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F ZJRHOWYRZCJNGN-UHFFFAOYSA-N 0.000 description 1
QHCVJWYSUYAUGJ-UHFFFAOYSA-N 2-[4-[5-[4-(4-butylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C(CCC)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F QHCVJWYSUYAUGJ-UHFFFAOYSA-N 0.000 description 1
FDEGGSXVOLEQHJ-UHFFFAOYSA-N 2-[4-[5-[4-(4-chlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound ClC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F FDEGGSXVOLEQHJ-UHFFFAOYSA-N 0.000 description 1
CXFZJAJCAJUYBL-UHFFFAOYSA-N 2-[4-[5-[4-(4-methylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound CC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F CXFZJAJCAJUYBL-UHFFFAOYSA-N 0.000 description 1
SFDXSAXMEXXYKO-UHFFFAOYSA-N 2-[4-[5-[4-(azidomethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound N(=[N+]=[N-])CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F SFDXSAXMEXXYKO-UHFFFAOYSA-N 0.000 description 1
ZUEITBVXYLBOCO-UHFFFAOYSA-N 2-[4-[5-naphthalen-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide Chemical compound C1=C(C=CC2=CC=CC=C12)C1=CC(=NN1C1=CC=C(C=C1)CC(=O)N)C(F)(F)F ZUEITBVXYLBOCO-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
DVNKXAKWCCJBOO-UHFFFAOYSA-N 4-[3-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=CC(C(F)(F)F)=N1 DVNKXAKWCCJBOO-UHFFFAOYSA-N 0.000 description 1
XWLLAYXVZPGHLH-UHFFFAOYSA-N 4-[5-(1H-pyrrol-2-yl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2NC=CC=2)=CC(C(F)(F)F)=N1 XWLLAYXVZPGHLH-UHFFFAOYSA-N 0.000 description 1
JFCWBZMXSFVWLI-UHFFFAOYSA-N 4-[5-(4-azidophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)N=[N+]=[N-])=CC(C(F)(F)F)=N1 JFCWBZMXSFVWLI-UHFFFAOYSA-N 0.000 description 1
SXHIXAHTLZKEGZ-UHFFFAOYSA-N 4-[5-(4-benzylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(CC=3C=CC=CC=3)=CC=2)=CC(C(F)(F)F)=N1 SXHIXAHTLZKEGZ-UHFFFAOYSA-N 0.000 description 1
BTNCDKSXLMHSQU-UHFFFAOYSA-N 4-[5-[4-(2,3-dichlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C=2C(=C(Cl)C=CC=2)Cl)=CC(C(F)(F)F)=N1 BTNCDKSXLMHSQU-UHFFFAOYSA-N 0.000 description 1
IUZWQZAEDBPILE-UHFFFAOYSA-N 4-[5-[4-(2,4,5-trichlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=CC(C(F)(F)F)=N1 IUZWQZAEDBPILE-UHFFFAOYSA-N 0.000 description 1
NWYXRBJJJVFKAO-UHFFFAOYSA-N 4-[5-[4-(3,5-dichlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C=2C=C(Cl)C=C(Cl)C=2)=CC(C(F)(F)F)=N1 NWYXRBJJJVFKAO-UHFFFAOYSA-N 0.000 description 1
KRCUADAWZWPWCB-UHFFFAOYSA-N 4-[5-[4-(3,5-dimethylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C=2C=CC(=CC=2)C=2N(N=C(C=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 KRCUADAWZWPWCB-UHFFFAOYSA-N 0.000 description 1
YSGQIHBTFRMMSV-UHFFFAOYSA-N 4-[5-[4-(4-azidophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)N=[N+]=[N-])=CC(C(F)(F)F)=N1 YSGQIHBTFRMMSV-UHFFFAOYSA-N 0.000 description 1
ZEJMWWLZBCGZTR-UHFFFAOYSA-N 4-[5-[4-(4-chlorophenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 ZEJMWWLZBCGZTR-UHFFFAOYSA-N 0.000 description 1
AYAWQPVJTYWMSP-UHFFFAOYSA-N 4-[5-[4-(4-methylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=CC=C(C=2N(N=C(C=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)C=C1 AYAWQPVJTYWMSP-UHFFFAOYSA-N 0.000 description 1
YIQAMJBWLRXADC-UHFFFAOYSA-N 4-[5-[4-[4-(azidomethyl)phenyl]phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(=CC=2)C=2C=CC(CN=[N+]=[N-])=CC=2)=CC(C(F)(F)F)=N1 YIQAMJBWLRXADC-UHFFFAOYSA-N 0.000 description 1
MQPLMBSDWYIIID-UHFFFAOYSA-N 4-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC=CC=2)=CC(C(F)(F)F)=N1 MQPLMBSDWYIIID-UHFFFAOYSA-N 0.000 description 1
YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108050008874 Annexin Proteins 0.000 description 1
102000000412 Annexin Human genes 0.000 description 1
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 1
108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
238000003512 Claisen condensation reaction Methods 0.000 description 1
102100024066 Coiled-coil and C2 domain-containing protein 1A Human genes 0.000 description 1
102100027995 Collagenase 3 Human genes 0.000 description 1
108050005238 Collagenase 3 Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000004057 DFT-B3LYP calculation Methods 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
241000283086 Equidae Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010040476 FITC-annexin A5 Proteins 0.000 description 1
206010053172 Fatal outcomes Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000910423 Homo sapiens Coiled-coil and C2 domain-containing protein 1A Proteins 0.000 description 1
101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100020870 La-related protein 6 Human genes 0.000 description 1
108050008265 La-related protein 6 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108010047956 Nucleosomes Proteins 0.000 description 1
101150000187 PTGS2 gene Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010070308 Refractory cancer Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
230000009925 apoptotic mechanism Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
125000005335 azido alkyl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
150000008331 benzenesulfonamides Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
OUEWZYXUSMEJCC-UHFFFAOYSA-N butane-1,3-dione Chemical compound CC(=O)C[C]=O OUEWZYXUSMEJCC-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
XOHPKEWFESGZPI-UHFFFAOYSA-N carbamic acid 5-(2,4-dimethylphenyl)-1-phenyl-3-(trifluoromethyl)pyrazole Chemical compound NC(O)=O.CC1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=CC=C1 XOHPKEWFESGZPI-UHFFFAOYSA-N 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000025084 cell cycle arrest Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
WKTKZNZWBRSPNY-UHFFFAOYSA-N chembl261143 Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C3=CC=CC=C3NC=2)=CC(C(F)(F)F)=N1 WKTKZNZWBRSPNY-UHFFFAOYSA-N 0.000 description 1
229940124443 chemopreventive agent Drugs 0.000 description 1
239000012627 chemopreventive agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000000547 effect on apoptosis Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical class 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000004896 high resolution mass spectrometry Methods 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
239000000677 immunologic agent Substances 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000686 lactone group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
235000020121 low-fat milk Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
229950008959 marimastat Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
210000001623 nucleosome Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
229940067157 phenylhydrazine Drugs 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012910 preclinical development Methods 0.000 description 1
YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
239000000718 radiation-protective agent Substances 0.000 description 1
208000016691 refractory malignant neoplasm Diseases 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000003211 trypan blue cell staining Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1